Purpose: To investigate efficacy of dexamethasone intravitreal (DEX) implant in treating refractory macular edema caused by retinal vein occlusion.
V ision loss from retinal vein occlusion (RVO) is frequently because of macular edema (ME). 1 The pathogenesis of ME after RVO is related to a variety of factors, including hydrostatic effects from increased venous pressure, inflammatory cytokines, dysregulation of endothelial tight junctions, and increased amount of vascular permeability factors, including vascular endothelial growth factor. [2] [3] [4] Macular laser photocoagulation, intravitreal anti-vascular endothelial growth factor agents, and intravitreal corticosteroids are commonly used treatments for ME caused by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). However, there are certain patients who develop refractory ME despite multiple treatments with the aforementioned modalities.
The dexamethasone (0.7 mg) intravitreal implant (DEX implant; OZURDEX, Allergan, Inc, Irvine, CA) was approved in 2009 to treat ME caused by RVO. It is contained in a solid bioerodible polymer for sustained release and can exert clinical effects for 3-6 months. The OZURDEX GENEVA study showed that both the 0.35 g and 0.7 mg DEX implant groups were both superior to sham in preventing visual acuity loss and improving the rapidity and incidence of visual acuity recovery in treatment-naive eyes with ME secondary to CRVO or BRVO. 5 The authors of this present study performed retrospective review of 0.7 mg DEX implant used to treat RVO-associated ME that had been refractory to multiple previous treatments.
Methods
This retrospective uncontrolled chart review studied patients diagnosed with refractory ME because of RVO, who were treated with their first DEX implant from March 2010 through July 2015. This project was reviewed by Indiana University's Institutional Review Board and considered exempt. Fluorescein angiography was performed on each patient on initial presentation to the clinic. Only patients diagnosed with CRVO or BRVO were included.
Refractory ME was diagnosed if the patients experienced persistent ME of at least 4 months duration despite at least 2 previous treatments, including any combination of macular laser photocoagulation, intravitreal triamcinolone acetonide, intravitreal bevacizumab, or intravitreal ranibizumab. In those patients who had undergone macular laser treatment, a grid pattern had been applied to areas with diffuse leakage, between 500 and 3,000 mm from the fovea; 532 nm laser was set to spot size of 50 mm at 0.05-0.1 seconds.
Exclusion criteria included other causes of ME, such as diabetic retinopathy or neovascular age-related macular degeneration. Patients were excluded if the baseline best-corrected visual acuity (BCVA) was better than 20/40, the central subfield thickness (CSFT) on spectral domain optical coherence tomography (OCT) was less than 300 mm, or if the foveal avascular zone was enlarged to greater than 1,000 mm. A minimum of 6 months of follow-up was required to be eligible for the study.
Patient charts were reviewed for eligibility, and data were extracted regarding the patient's age, gender, previous interventions, and CSFT. The BCVA, CSFT, intraocular pressure (IOP), lens status, treatment dates from the initial visit, and follow-up visits were recorded. Snellen visual acuity was converted to logarithm of minimal angle of resolution (logMAR) for statistical analysis. In cases of missing data points, the last observation was carried forward. Regression analysis was performed on the individual data to determine correlations between the independent variables of number of days of follow-up or number of DEX implants and the dependent variables of logMAR visual acuity or CSFT. Mean values for logMAR visual acuity and CSFT, as well as SD and range, were calculated at each follow-up visit.
On all visits, response to treatment was evaluated subjectively by Snellen visual acuity with best correction and objectively by biomicroscopic examination and Zeiss Cirrus spectral domain OCT (Carl Zeiss Meditec, Jena, Germany). In all cases, the use of DEX implant and its potential risks and benefits were discussed with the patients before signing an informed consent. The DEX implant was injected 3.5-4 mm posterior to the limbus under aseptic conditions. Subsequent injections were administered on an as needed basis for persistent ME on OCT affecting the foveal center.
Results
The study included 22 eyes of 22 patients with ME caused by venous occlusion (10 patients with BRVO and 12 with CRVO). The mean age was 70 ± 17.6 years (range 46-86 years). There were 9 males and 13 females; 12 patients were phakic (55%) and 10 were pseudophakic (45%) at the initiation of the study. All patients experienced ME for at least 4 months duration (mean 20.8 ± 17.6 months, range 4-72 months) before undergoing treatment with DEX implant (Table 1) .
Before treatment with DEX implant, this group of eyes received an average of 7 previous treatments (22 eyes received 2-19 treatments including macular laser, intravitreal bevacizumab, ranibizumab, or triamcinolone acetonide). The mean washout period, in which no treatment was given before initial DEX implant, was 133 ± 97 days (median 117 days, range 38-402 days). See Table 2 .
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None of the authors has any conflicting interests to disclose. Figure 1 ). A statistically significant relationship was found between mean logMAR visual acuity and number of days followed (P = 0.006), but not for mean logMAR visual acuity and number of DEX implants administered (P = 0.99).
Compared with BRVO patients, who started with better mean BCVA, CRVO patients experienced a greater initial improvement of mean BCVA. Ultimately, BRVO patients maintained an improved 6-month and 1-year mean BCVA, whereas the CRVO patients experienced loss of mean BCVA (Table 3 and Figure 1 ).
With respect to ME as measured by OCT, before the initial DEX implant, CSFT for all patients averaged 506 ± 150 mm. At the first follow-up visit at an average of 7 weeks later, there was meaningful improvement to a mean of 292 ± 134 mm (42% reduction). Mean CSFT increased to 352 ± 152 mm and 356 ± 131 mm at 6 months (after mean 1.5 ± 0.51 DEX implants) and 12 months (after mean 2.2 ± 0.85 DEX implants) follow-up, respectively (Table 3 and Figure 2 ). A statistically significant relationship was found between mean CSFT and number of DEX implants administered (P = 3.28 · 10 −9 ), but not for mean CSFT and number of days followed (P = 0.40).
The BRVO patients exhibited a more favorable baseline mean CSFT compared with the CRVO group. Mean CSFT improved meaningfully for both BRVO and CRVO groups after the first DEX implants but worsened on subsequent visits (Table 3 and Figure 2 ).
We performed analysis to determine whether duration of ME before treatment with DEX correlated with treatment response. Patients with ME duration ,12 months had a greater response to the first treatment, as mean logMAR improved by 0.23 ± 0.07 (0.60-0.37) and mean CSFT improved by 234 ± 31 mm (539-305 mm). Patients with .12 months duration of ME had a smaller improvement, as mean logMAR improved by 0.08 ± 0.07 (0.55-0.47) and mean CSFT improved by 199 ± 52 mm, (479-280 mm). The difference in logMAR visual acuity was statistically significant (P = 0.05), whereas the difference in CSFT was not significant (P = 0.27).
With respect to IOP, mean IOP before the first DEX implant was 16.7 ± 3.8, which increased to 21.2 ± 6 at the first follow-up visit (Table 3) . Five of 22 patients (22.7%) were discontinued from additional treatment with DEX implant because of development of ocular hypertension (IOP . 30). These patients had a minimum of 2 DEX implants (similar to the mean of 2.2 DEX implants for all patients) and hence were considered in the final analysis. All 5 patients showed improved IOP (,21 mmHg) after discontinuation of DEX implant and initiation of one topical IOP-lowering agent.
Regarding lens status, 6 of 12 initially phakic patients (50%) experienced cataract progression for which they underwent cataract surgery. This subset of patients was followed out to their most recent clinic visit (mean 970 days follow-up). Visually significant cataract was observed after a mean of 446 ± 36 days and 3.17 ± 0.75 DEX implants. The phakic patients showed mean baseline BCVA of 20/72 and 1-year mean BCVA of 20/105. The baseline pseudophakic patients exhibited worse mean baseline BCVA of 20/ 119 and 1-year BCVA of 20/170 ( Figure 3 ). There were no cases of endophthalmitis, retinal detachment, or death throughout the study period.
Conclusion
This study evaluated outcomes of repeated DEX implant injections to treat refractory ME caused by RVO. The results suggest that DEX implant is effective in reducing CSFT for a sustained period, but improvements in BCVA were transient. The greatest improvement in mean CSFT (42%) occurred after the first DEX implant. The logMAR visual acuity followed an undulating pattern, correlating with DEX treatment and its duration of action of approximately 3-4 months. The CRVO patients had a greater initial improvement in mean BCVA and mean CSFT, likely because of the fact that their baseline values were worse (with less potential for a ceiling effect), although ultimately only the BRVO subgroup maintained stable improvement in mean BCVA.
There was a high incidence of visually significant cataract (particularly posterior subcapsular cataracts) that developed in phakic patients receiving repeated DEX implants, and this can partially account for the deteriorating BCVA. However, baseline pseudophakic patients had a similar deterioration of BCVA at 1 year follow-up, suggesting that cataract formation cannot fully account for deterioration in vision. Other studies have suggested that patients with chronic edema fare poorly. Even patients with ME for 6 months duration fare worse than those treated promptly; for example, in the pivotal Phase 3 randomized prospective clinical trial of ranibizumab for ME after CRVO (CRUISE), Mean logMAR visual acuity in relation to number of days of follow-up after first treatment in eyes treated with 0.7 mg intravitreal dexamethasone implant. Visual acuity followed a saw-toothed pattern that roughly correlated to the injection schedule, although at last followup it had significantly worsened compared with baseline. The BRVO group had relatively favorable outcomes compared with the CRVO group.
sham patients who crossed over at 6 months to ranibizumab treatment did not recover to the same degree at 12 months, as those treated with ranibizumab from the start. 6 In the current study, the neuroretinal atrophy caused by chronic ME may be responsible for the worsening of vision in these patients despite reduction of ME. It has been reported that patients with RVO with poor visual acuity (logMAR , 1.0) despite resolution of ME had OCT findings of inner retinal thinning (suggesting atrophy). The patients with relatively good visual acuity (logMAR , 0.3) had the ME above the inner segments of the ellipsoid zone and had an intact ellipsoid zone more frequently after resolution of ME. 7 Our analysis indicates that patients with duration of ME .12 months before treatment with DEX had statistically significant less improvement in logMAR after one treatment compared with those with ,12 months duration, which may support these findings, as greater duration of ME would be more likely to cause chronic structural alterations in the retina despite reduction of edema. The difference in reduction of macular thickness was not statistically significant between these two groups.
These results show a more notable improvement in CSFT but less improvement in visual acuity compared with results reported by Sharareh et al, 8 who studied eyes with RVO-related ME refractory to multiple bevacizumab injections. Alshahrani et al reported that a single DEX implant caused a statistically significant improvement in both visual acuity and CSFT in patients with refractory ME, which peaked at 1 and 3 months and then lost significance by 6 months. 9 Our results followed a similar pattern of significant improvement of mean BCVA and mean CSFT within the first 7 weeks, with diminished effects by 3 months follow-up and onward, despite repeated DEX implants.
Limitations of this study include its uncontrolled retrospective nature without a standardized refraction protocol, lack of standardized regimen before initiating DEX treatment, and limited sample size. Furthermore, statistical analyses in retrospective studies are inherently flawed with hindsight bias and consequently meant to be exploratory in nature for hypothesis generation. Additionally, the washout period had a wide range of 38-402 days, which was likely because of poor follow-up for selective patients who had failed to respond adequately to previous treatments. However, consistent with previous studies, this study suggests that DEX may treat chronic RVO-related ME refractory to previous anti-vascular endothelial growth factor treatment or laser photocoagulation, which is also consistent with the mechanism of action of corticosteroids. The DEX implants reduce several pro-permeability proteins and inflammatory mediators, providing a multitargeted approach in treating RVO. 10 Furthermore, in a recent large prospective trial of another corticosteroid, fluocinolone implant, for diabetic ME, treatment was more effective in those eyes with chronic diabetic ME, and the authors speculated that chronic diabetic ME was driven by subclinical inflammation, compared with acute diabetic ME which is driven by vascular endothelial growth factor. 11 It is biologically plausible that a similar phenomenon occurs in chronic refractory ME because of RVO. Nevertheless, this current study, along with the previous studies discussed herein, suggest that chronic edema is best avoided, given the guarded prognosis. Clearly, further study of treatment regimens for refractory and/or chronic ME is warranted, given the visual disability caused.
Key words: BRVO, CRVO, corticosteroids, dexamethasone, macular edema, optical coherence tomography, OZURDEX. Fig. 2 . Mean CSFT in relation to number of days of follow-up after first treatment in eyes treated with 0.7 mg intravitreal dexamethasone implant. The CSFT reduced drastically in the first 7 weeks, although it later plateaued on subsequent visits. Fig. 3 . Subgroup analysis of baseline phakic versus pseudophakic eyes indicates that both groups had initial improvement of mean logMAR visual acuity with intravitreal dexamethasone treatment. However, after approximately 180 days follow-up, visual acuity began to worsen in both groups.
